322 related articles for article (PubMed ID: 24742294)
1. The role of the TP73 gene and its transcripts in neuro-oncology.
Jancalek R
Br J Neurosurg; 2014 Oct; 28(5):598-605. PubMed ID: 24742294
[TBL] [Abstract][Full Text] [Related]
2. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
Murray-Zmijewski F; Lane DP; Bourdon JC
Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
[TBL] [Abstract][Full Text] [Related]
3. The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis.
Holcakova J; Ceskova P; Hrstka R; Muller P; Dubska L; Coates PJ; Palecek E; Vojtesek B
Cell Mol Biol Lett; 2008; 13(3):404-20. PubMed ID: 18350258
[TBL] [Abstract][Full Text] [Related]
4. Role of p73 in malignancy: tumor suppressor or oncogene?
Stiewe T; Pützer BM
Cell Death Differ; 2002 Mar; 9(3):237-45. PubMed ID: 11859406
[TBL] [Abstract][Full Text] [Related]
5. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
6. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
7. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
8. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
9. p73 in apoptosis.
Stiewe T; Pützer BM
Apoptosis; 2001 Dec; 6(6):447-52. PubMed ID: 11595834
[TBL] [Abstract][Full Text] [Related]
10. p53 Family isoforms.
Bourdon JC
Curr Pharm Biotechnol; 2007 Dec; 8(6):332-6. PubMed ID: 18289041
[TBL] [Abstract][Full Text] [Related]
11. The functional domains in p53 family proteins exhibit both common and distinct properties.
Harms KL; Chen X
Cell Death Differ; 2006 Jun; 13(6):890-7. PubMed ID: 16543939
[No Abstract] [Full Text] [Related]
12. Regulation of p73 activity by post-translational modifications.
Conforti F; Sayan AE; Sreekumar R; Sayan BS
Cell Death Dis; 2012 Mar; 3(3):e285. PubMed ID: 22419114
[TBL] [Abstract][Full Text] [Related]
13. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis.
Buhlmann S; Racek T; Schwarz A; Schaefer S; Pützer BM
J Mol Biol; 2008 Apr; 378(1):20-30. PubMed ID: 18342333
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
16. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
17. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
Emmrich S; Wang W; John K; Li W; Pützer BM
Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
[TBL] [Abstract][Full Text] [Related]
18. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
Hassan HM; Dave BJ; Singh RK
Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
[TBL] [Abstract][Full Text] [Related]
19. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.
Yu J; Baron V; Mercola D; Mustelin T; Adamson ED
Cell Death Differ; 2007 Mar; 14(3):436-46. PubMed ID: 16990849
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of p73 and p53 regulation and effector functions.
Fang L; Lee SW; Aaronson SA
J Cell Biol; 1999 Nov; 147(4):823-30. PubMed ID: 10562283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
